<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923076</url>
  </required_header>
  <id_info>
    <org_study_id>HIVECT-1501</org_study_id>
    <nct_id>NCT02923076</nct_id>
  </id_info>
  <brief_title>HIV Eradication Through Cord-blood Transplantation</brief_title>
  <acronym>HIVECT</acronym>
  <official_title>A Prospective Clinical Research Protocol of Allogeneic CCR5 delta32/delta32 Cord Blood Cell Transplantation to Cure HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic cell transplantation from a CCR5 Δ32/Δ32 unrelated donor, performed
      for the first time in the &quot;Berlin patient&quot;, provides the only evidence to date of long-term
      control of HIV infection. Stringent criteria to select human leukocyte antigen (HLA)-matched
      conventional donors and low prevalence of the CCR5 Δ32/Δ32 homozygous genotype (&lt;1%) made the
      pursuit of &quot;patient number 2&quot; unsuccessful for many years. Cord blood (CB) transplantation
      allows more permissive HLA-matching criteria, making the search for HLA-compatible Δ32/Δ32 CB
      units potentially feasible for transplantation of HIV-infected individuals.

      The investigator team involved in this trial has recently reported the first such case of
      CCR5 delta32/delta32 CB transplantation in a patient with HIV infection, showing a reduction
      of the patient's latent viral reservoir and, upon achievement of full CB chimerism,
      resistance of his CD4 T-lymphocytes to infection by HIV. This proof of concept led the
      Spanish National Transplant Organization (ONT) to generate an inventory of over 150 CCR5
      Δ32/Δ32 CB units readily available for transplant.

      From this initial evidence and repository of CB units, financial support from the Fundación
      Mutua Madrileña (FMM) has allowed the investigators to launch this first pilot clinical trial
      in this indication. The study was launched in January 2016 at Hospital Universitario Puerta
      de Hierro Majadahonda. All HIV virology and reservoir analyses are carried out by the AIDS
      Immunopathology Unit at the Spanish Instituto de Salud Carlos III. Three additional
      transplant centres in Spain will also shortly open the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV infection and viral reservoir - Cell-associated total HIV-1 DNA in CD4 T cells from peripheral blood and from gut-associated lymphoid tissue (GALT): Expressed in copies per million cells.</measure>
    <time_frame>Between 6-12 months: following discontinuation of antiretroviral therapy upon full CCR5 delta32/delta32 cord blood chimerism</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV infection and viral reservoir - Viral copies in plasma and culture supernatants by Single Copy Assay and COBAS AMPLICOR HIV-1 Monitor v.1.5: Expressed in copies per mL.</measure>
    <time_frame>Between 6-12 months: following discontinuation of antiretroviral therapy upon full CCR5 delta32/delta32 cord blood chimerism</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ex vivo HIV-1 infection tests on CCR5 d32/d32-derived recipients CD4 T cells - Using patient's primary isolates and laboratory strains of HIV-1 with CCR5 and CXCR4 tropism: Expressed in ng/mL of p24 ELISA.</measure>
    <time_frame>Between 6-12 months: following discontinuation of antiretroviral therapy upon full CCR5 delta32/delta32 cord blood chimerism</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Study treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CCR5 delta32/delta32 cord blood transplantation</intervention_name>
    <arm_group_label>Study treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inform consent, that will be previously approved by the board, is required in order to
             carry out any procedure related to the study.

          -  HIV infection.

          -  Hematologic malignancies or any other condition with a standard indication for
             allogeneic hematopoietic cell transplantation. See indications by the European Society
             for Blood and Marrow Transplantation (EBMT). [Sureda A. et al. Indications for allo-
             and auto-SCT for haematological diseases, solid tumours and immune disorders: current
             practice in Europe, 2015. Bone Marrow Transplantation (2015) 50, 1037-1056.]

          -  Lack of HLA-identical related donor

          -  Availability of at least one cord blood unit CCR5 delta32 homozygous that meets
             quality standards.

        Exclusion Criteria:

          -  Availability of HLA-identical related donor

          -  Contraindication for allogeneic stem cell transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Duarte Palomino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro- Majadahonda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Esther Martínez Muñoz</last_name>
    <phone>0034 911917809</phone>
    <email>mmartinezmunoz@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Salcedo</last_name>
    <phone>0034 911916481</phone>
    <email>isabel.salcedo@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro- Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Esther Martínez Muñoz</last_name>
      <phone>0034 911917809</phone>
      <email>mmartinezmunoz@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Salcedo</last_name>
      <phone>0034 911916481</phone>
      <email>isabel.salcedo@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 30, 2016</last_update_submitted>
  <last_update_submitted_qc>October 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Rafael F. Duarte</investigator_full_name>
    <investigator_title>Head of the Hematopietic Cell Transplantation program</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

